Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging

American Journal of Neuroradiology

Volumn 34, Issue 12, 2013, Pages 2278-2286

  Suh, C H ^a   Kim, Ho Sung ^a   Choi, Y J ^a   Kim, N ^a   Kim, S J ^a  

^a University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERATE MEGLUMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DYNAMIC CONTRAST ENHANCED PERFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFORMANCE; PREDICTION; PREDICTIVE VALUE; PSEUDOPROGRESSION; QUANTITATIVE ANALYSIS; RADIATION FIELD; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84890473600     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3634     Document Type: Article

References (21)

1. Gasparetto EL, Pawlak MA, Patel SH, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 2009;250:887-96
2. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol 2008;26:4359; author reply 4360
3. Fatterpekar GM, Galheigo D, Narayana A, et al. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum - use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol 2012;198:19-26
4. Hu X, Wong KK, Young GS, et al. Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma. J Magn Reson Imaging 2011;33:296-305
5. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944-50
6. Roberts C, Issa B, Stone A, et al. Comparative study into the robustness of compartmental modeling and model-free analysis in DCEMRI studies. J Magn Reson Imaging 2006;23:554-63
7. Cheng HL. Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach. J Magn Reson Imaging 2009;30:864-72
8. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73
9. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-89
10. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72
11. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-57
12. Tozer DJ, Jager HR, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20:49-57
13. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45
14. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-59
15. Narang J, Jain R, Arbab AS, et al. Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro Oncol 2011;13:1037-46
16. Kiselev VG. On the theoretical basis of perfusion measurements by dynamic susceptibility contrast MRI. Magn Reson Med 2001;46:1113-22
17. Larsen VA, Simonsen HJ, Law I, et al. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 2013;55:361-69
18. Walker-Samuel S, Leach MO, Collins DJ. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006;51:3593-602
19. Bisdas S, Naegele T, Ritz R, et al. Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. Acad Radiol 2011;18:575-83
20. Levy LM. What is right about MRI permeability studies. AJNR Am J Neuroradiol 2005;26:3-4
21. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552-58